Close Menu

NEW YORK – Becton Dickinson revealed last week that it has acquired NAT Diagnostics, a molecular diagnostics firm focused on rapid point-of-care testing. The NAT Dx isothermal technology will be further developed by BD with an eye toward offering customers decentralized molecular testing options in early 2023.

The deal was signed last year, according to BD, but it was not finalized until last quarter. Terms of the agreement have not been disclosed.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

A new study finds that three dimensional facial scans may be able to aid in diagnosing rare genetic diseases.

The Lancet and the New England Journal of Medicine have retracted two COVID-19 papers due to concerns about the data used in their analyses.

Lawmakers plan to introduce a bill that aims to prevent the theft of US-funded research, according to the Wall Street Journal.

In Science this week: analysis of ancient Caribbean islanders' genomes suggests at least three waves of migration into the region,  DNA barcoding of microbial spores, and more.

Jul
15
Sponsored by
LGC SeraCare Life Sciences

Cancer immunotherapy is an exciting new advance for the successful treatment of many forms of metastatic cancer.